中国耳鼻咽喉头颈外科2024，Vol.31Issue(2)：69-73,5.DOI:10.16066/j.1672-7002.2024.02.001
桂滇黔地区局部晚期鼻咽癌同期放化疗联合尼妥珠单抗靶向治疗前瞻性临床研究
Prospective clinical study of concurrent chemoradiotherapy combined with nituzumab for targeted treatment of locally advanced nasopharyngeal carci noma in Guangxi,Yunnan and Guizhou regions
摘要
Abstract
OBJECTIVE To explore the clinical effect of concurrent chemoradiotherapy combined with nituzumab in the treatment of locally advanced nasopharyngeal carcinoma in Guangxi,Yunnan and Guizhou.METHODS A total of 80 patients with locally advanced nasopharyngeal carcinoma who were pathologically confirmed and admitted to Affiliated Hospital of Youjiang Ethnomedicine from July 2021 to July 2022 from ethnic minority areas near the border of Guangxi,Yunnan and Guizhou were selected as the subjects of this study.They were randomly divided into control group(standard concurrent chemoradiotherapy)and observation group(combined treatment with nituzumab on the basis of control group),with 40 cases in each group.The levels of tumor markers,oxidative stress indicators,adverse reactions,complications,and recent clinical efficacy of the two groups were compared.RESULTS After treatment,the levels of superoxide dismutase(SOD),cytokeratin 19 fragment antigen21-1(CYFRA21-1),squamous cell carcinoma associated antigen(SCCAg)and serum ferritin(SF)were significantly decreased in both groups,while nitric oxide(NO)and malondialdehyde(MDA)were significantly increased.The levels of SCCAg,SF,CYFRA21-1,NO and MDA in observation group were lower than those in control group,and the level of SOD was higher than those in control group(P<0.05).Compared with the control group,the objective response rate(ORR)in the observation group was increased(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).There was no significant difference in the incidence of complications between the two groups(P>0.05).CONCLUSION Concurrent chemoradiotherapy combined with nituzumab can effectively improve the short-term survival rate and clinical efficacy of patients with locally advanced nasopharyngeal carcinoma,regulate tumor markers and oxidative stress levels,and alleviate the disease.关键词
治疗,临床研究性/局部晚期鼻咽癌/同期放化疗/尼妥珠单抗/肿瘤标志物Key words
Therapies,Investigational/locally advanced nasopharyngeal carcinoma/concurrent chemoradiotherapy/nituzumab/tumor marker引用本文复制引用
张倬彬,张富亿,姜秋兰,李晓宇,林洁,叶霞,潘柳叶,苏群英..桂滇黔地区局部晚期鼻咽癌同期放化疗联合尼妥珠单抗靶向治疗前瞻性临床研究[J].中国耳鼻咽喉头颈外科,2024,31(2):69-73,5.基金项目
百色市科学研究与技术开发计划项目(20213233) （20213233）
